Bradbury has executed a US$3 million strategic investment in IGC Pharma (NYSE American: IGC) via an unregistered private placement of common stock. The capital allocation is mandated to support the advancement of the issuer’s clinical pipeline, including ongoing Alzheimer’s disease trials, and general corporate working capital.
In March 2024, Bradbury completed a strategic investment in clinical-stage pharmaceutical company IGC Pharma, Inc. (NYSE American: IGC). The transaction was structured as an unregistered private placement of common stock, yielding gross proceeds of US$3 million to the issuer.
Capital from this placement is explicitly directed toward the advancement of the issuer’s clinical research pipeline. This includes providing funding for the ongoing investigational trials of IGC-AD1, a therapeutic candidate targeting agitation in Alzheimer’s disease, alongside standard corporate working capital. The transaction reflects Bradbury’s continued deployment of capital into regulated, clinical-stage life science mandates.
Source citation: IGC Pharma, Inc. Corporate Disclosures, March 12, 2024.
